Inhibrx EBITDA 2020-2022 | INBX

Inhibrx ebitda from 2020 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Inhibrx Annual EBITDA
(Millions of US $)
2021 $-74
2020 $-56
2019 $-37
Inhibrx Quarterly EBITDA
(Millions of US $)
2022-03-31 $-28
2021-12-31 $-19
2021-09-30 $-18
2021-06-30 $-19
2021-03-31 $-18
2020-12-31 $-17
2020-09-30 $-11
2020-06-30 $-13
2020-03-31 $-16
2019-12-31
2019-09-30 $-13
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.443B $0.007B
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.938B 9.97
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.718B 16.92
Biohaven Pharmaceutical Holding (BHVN) United States $10.276B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.817B 46.07
Emergent Biosolutions (EBS) United States $1.560B 6.68
Myovant Sciences (MYOV) United Kingdom $1.185B 0.00
Zymeworks (ZYME) Canada $0.306B 0.00
Gelesis Holdings (GLS) United States $0.112B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00